Menu Philippe 4

What Happened Philippe Menu, Chief Medical Officer of SOPHiA GENETICS (SOPH), received equity awards on April 2, 2026. The filing shows a grant of 112,936 restricted stock units (RSUs) and a separate derivative award of 164,671 shares (reported as a grant/award), both reported at $0.00 (no cash paid). These are compensation awards (not open-market purchases or sales) and will vest over time per the company’s equity plan.

Key Details

• Transaction date: April 2, 2026; Form 4 filed April 3, 2026 (timely).
• Awards: 112,936 RSUs (reported line A) and 164,671 derivative/share-option-style awards (reported line A); both at $0.00.
• Vesting (per footnotes): RSUs — 25% vests April 2, 2027, remaining 75% vests in equal quarterly installments through April 2, 2030 (F1). Derivative/option award — 25% vests April 2, 2027, then vests in equal monthly installments through April 2, 2030 (F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant. No sale, exercise, or tax-withholding event reported in the excerpt.

Context These awards are time‑vesting compensation common for executives; they do not represent immediately transferable shares or an immediate cash gain. The derivative award will vest over time and, depending on the award type, may require exercise under plan terms before shares are received. This filing documents compensation, not a market buy/sell signal.